top of page

Retina Clinical Trial Unit
視網膜疾病臨床實驗組

Overview 概述

The University of Hong Kong Retinal and Macular diseases Clinical Trials Research group is focused on diseases of the retina including those related to diabetes, age related degeneration or vascular occlusions. Previous treatments for such diseases have been limited and often ineffective. With the introduction of anti VEGF, millions of patients worldwide have been successfully treated for their various retinal or macular diseases.

香港大學視網膜及黃斑部疾病臨床試驗研究小組專注於視網膜疾病，包括與糖尿病、年齡相關性退化或血管閉塞相關的疾病。以前對這些疾病的治療是有限的，而且常常是無效的。隨著抗 VEGF 藥物的引入，全球數百萬患者的各種視網膜或黃斑疾病已得到成功治療。


Our group has been closely involved in the testing and introduction of these anti VEGF drugs with some of the largest clinical trials in the world, with a hand in many of the current drugs on the market in Hong Kong today. By bringing in newer, longer lasting, more effective drugs to the patients, we hope to also minimise the treatment burden of the patient. Although the use of these drugs have been shown to be safe and effective, our team continues to also work on optimising the dosage and minimising the side effects by closely working with the network of medical retinal experts worldwide. The landmark clinical trials we have been involved with are listed below which include the testing of current drugs such as ranibizumab (Lucentis), and aflibercept (Eylea) or upcoming drugs such as the port delivery system,  conbercept, faricimab and abicipar.

我們的團隊一直密切參與這些抗 VEGF 藥物的測試和推出，並參與了世界上一些最大規模的臨床試驗，並參與了當今香港市場上的許多當前藥物。通過為患者帶來更新、更持久、更有效的藥物，我們也希望將患者的治療負擔降至最低。儘管這些藥物的使用已被證明是安全有效的，但我們的團隊還通過與全球醫學視網膜專家網絡密切合作，繼續努力優化劑量並最大限度地減少副作用。下面列出了我們參與的具有里程碑意義的臨床試驗，其中包括對當前藥物的測試，如雷珠單抗 (Lucentis) 和阿柏西普 (Eylea) 或即將推出的藥物，如port delivery system、康柏西普、法瑞西單抗和阿比西帕。

Ongoing Clinical Trials Projects 正在進行的臨床試驗項目

Age Related Macular Degeneration 年齡相關性黃斑變性  (黃斑病變)：

  1. Voyager - Real-World, Long-Term Data Collection To Gain Clinical Insights Into Roche Ophthalmology Products - (Roche)

  2. Oculis (DX219): A Phase 2/3 Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema (IRB UW-22-692) - on going (Oculis SA)

  3. Salween (MR43808): A PHASE IIIb/IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY - on going (Roche)

  4. DIAGRID (MR42410): A Phase IIIB, Multicentered, Randomized, visual assessor-masked study of the effectivement and safetly of a 36 week refill regimen for the port delivery system with ranibizumab vs aflibercept treat & extend in subjects with neovascular Age-related macular degeneration - on going (Roche)

  5. (ONL1204-GA-001): A Phase 1b Multicenter, Randomized, Controlled, Multi-dose Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients with Geographic Atrophy (GA) Associated with Age-related Macular Degeneration (AMD) - on going (ONL Therapeutics) 

  6. Avonelle-X (X/GR42691): A Multicenter, open-label extension study to evaluate the long term safety and tolerability of Faricimab in patients with Neovascular age-related macular degeneration - (Sponsored by Roche Holding AG)

  7. Everest & Planet follow up study: To determine long-term outcomes, recurrence rates, and treatment needs in PCV - (in collaboration with Singapore Eye Research Institute)

​

Diabetic Macular diseases 糖尿病性黃斑部疾病（糖尿上眼）：

  1. Ripple: (IBE-814-IVT-1): Evaluation of Safety and Efficacy of the IBE-814 Intravitreal Implant in Patients with Diabetic Macular Oedema and Macular Oedema due to Retinal Vein Occlusion - on going (Ripple Therapeutics)

  2. RHONE X: (GR41987) A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema - (Sponsored by Roche Holding AG)

 

Retinal Vein occlusion 視網膜血管閉塞：

  1. Balaton (GR41984) A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to branch retinal vein occlusion - (Sponsored by Roche Holding AG)

  2. Comino (GR41986) A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion - (Sponsored by Roche Holding AG)

​

Myopic Maculopathy (近視性黃斑病變)：

  1. Poyang - (CR44829) A PHASE III, Multicenter, randomized, Double-masked, Active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with choroidal neovascularization secondary to pathological myopia - Roche

​

Previously completed International multicentered, clinical trials 之前完成的國際多中心、臨床試驗：

  1. VIVID East: A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema - completed 2016 (Sponsored by Bayer AG)

  2. CEDAR/SEQUOIA: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration - completed 2019 (Sponsored by Allergan)

  3. PLANET: A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic therapy as indicated in subjects with polypoidal choroidal vasculopathy (Aflibercept) - completed 2018 (Sponsored by Bayer AG)

  4. EVEREST2: A 24-month, phase IV, randomized, double masked, multicenter study of ranibizumab monotherapy or ranibizumab in combination with verteporfin photodynamic therapy on visual outcome in patients with symptomatic macular polypoidal choroidal vasculopathy - completed 2017 (Sponsored by Novartis International AG)

  5. RHINE (GR40398): A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of RO6867461in patients with diabetic macular edema - (Roche Holding AG)

  6. LUCERNE (40844): A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with neovascular age-related macular degeneration - (Sponsored by Roche Holding AG)

  7. AMGEN (20170542): A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration - (Sponsored by AMGEN Inc)

Nick_org.jpg

Dr Nicholas S.K. Fung

馮兆基醫生

Honorary Clinical Associate Professor

名譽臨床副教授

Research Team Members 研究團隊成員

Research Staff

  • Ella Lee – Project Officer

  • Dr. Mehnaz Quddus – Research Assistant

  • Winnie Hui – Research Assistant

  • Leung Man Kei - Lead Research Optometrist
    Degree: Registered Optometrist (Part 1), BSc (Hons) in Optometry, The Hong Kong Polytechnic University

  • Stephen Chan - Senior Research Assistant & Orthoptist
    Degree: Double Degree in Bachelor of Science and Bachelor of Law from The University of Hong Kong and University of London    ​

 

Postgraduate Students

  •  Jennifer Tsui, PhD (Ophthalmology) candidate

 

Ophthalmologists

  • Dr. Bonnie Choy, Clinical Associate Professor, Department of Ophthalmology, University of Hong Kong

  • Dr. Angie Fong, Clinical Associate Professor, Department of Ophthalmology, University of Hong Kong

  • Dr. Qing Li, Associate Consultant, Grantham Hospital

  • Dr. Stephanie Yuk, Associate Consultant, Grantham Hospital

  • Dr. Christie Lun, Resident, Grantham Hospital

  • Dr. Jason Pang, Resident, Grantham Hospital

  • Dr. Jeffery Lee, Resident, Grantham Hospital

  • Dr. Lam Wai Yun, Resident, Grantham Hospital

  • Dr. Rachel Cheung, Resident, Grantham Hospital

Contact Information 聯絡方法

Email: vitreoretinal@hku.hk
Phone: (852) 3962 1405
Address: Room 301, Level 3 Block B, Cyberport 4 100 Cyberport Road, Hong Kong

bottom of page